Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
TriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Possible Fraud - Contact Levi & Korsinsky Today
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Lost Money on TriSalus Life Sciences, Inc. (TLSI)? Contact Levi & Korsinsky to Protect Your Rights
TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
TriSalus Life Sciences Proposes Public Offering
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
Terumo (OTCMKTS:TRUMY) vs. TriSalus Life Sciences (NASDAQ:TLSI) Critical Survey
Contrasting Stagezero Life Sciences (OTCMKTS:SZLSF) and TriSalus Life Sciences (NASDAQ:TLSI)
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
AWM Investment Company Inc. Acquires New Shares in TriSalus Life Sciences, Inc. $TLSI
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Reports Q3 Loss, Tops Revenue Estimates
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
TriSalus Life Sciences (NASDAQ:TLSI) Shares Down 5.3% – Here’s Why
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript